ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 2570

Urinary Cellular Profile as a Biomarker for Proliferative Lupus Nephritis

Amira El Gerby 1, Abeer Abdelati 2, Hanaa Donia 3 and Nouran Eshak4, 1Rheumatology Department, Faculty of Medicine, Alexandria University, Egypt, Alexandria, Egypt, 2alexandria university, alexandria, Egypt, 3Clnical and Chemical Pathology Department, Faculty of Medicine, ALexandria University, Alexandria, Egypt, 4Rheumatology Unit, Internal Medicine Department, Faculty of Medicine, Alexandria University, Lubbock, TX

Meeting: ACR/ARP Annual Meeting 2019

Keywords: Lupus nephritis, lymphocytes, Urinary Biomarkers and macrophages

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: SLE – Clinical Poster III: Treatment

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Proliferative lupus nephritis (LN) is one of the most common and serious manifestations of SLE and is a major cause of morbidity. A search for the ideal biomarker for LN is still underway, one that can be used for early detection, and correlate with the class & activity of LN. Urine is normally devoid of leucocytes, however, it has been observed that macrophages and T-lymphocytes are routinely present in the urine of LN patients and those with other proliferative renal diseases. This provided the idea for their potential use as biomarkers for proliferative LN. The objective is to study the urinary CD4+, CD8+ T Lymphocytes, and CD14+ monocytes in patients with proliferative lupus nephritis, and explore their use as a biomarker for LN. 

Methods: Our subjects included 30 patients with biopsy-proven proliferative LN (Group A) and 30 SLE patients without clinical or lab evidence of LN as controls (Group B). Laboratory investigations included serum creatinine, urine analysis, protein: creatinine ratio, anti-ds DNA Ab, C3 and C4. For the flow cytometric analysis, 100 ml of freshly voided urine in a sterile container were obtained from patients and controls. All samples were processed within 2-4 hours of collection to ensure viability of the cells. Urine mononuclear cell count was done using a hemocytometer. The urine samples were centrifuged then washed twice by phosphate-buffered saline/bovine serum albumin (PBS/BSA) & re-suspended in about 300 μls PBS. The cells were stained with anti CD8- FITC, anti CD4- PE, anti CD14-PERCP and anti- CD3-APC monoclonal antibodies. The flow cytometric analysis was done using Becton Dickinson, FACS Calibur multi-parameter flow cytometer equipped with BD CellQuest Pro software for data analysis. 

Results:  CD14 + cells were the most abundant cells in the urine of LN patients. The mean numbers of urinary CD8+, CD4+ and CD14+ cells/ml were significantly higher in patients with LN (405.6 ± 200.0, 281.1 ± 195.3, and 1554.7 ± 606.8 respectively) than in those without (39.30 ± 17.56, 34.33 ± 16.41, and 161.17 ± 90.91 respectively). AUC for ROC = 1.0 for all 3 markers with CD8+ >85 cells/ml, CD4+ >80 cells/ml, and CD14+ >400cells/ml being observed exclusively in LN. 
The cell counts correlated significantly with the protein: creatinine ratio, but not with other markers of disease activity.  
The CD4: CD8 ratio was significantly lower in LN patients (0.69 ± 0.21) than in those without (0.91 ± 0.31).
Urinary CD14+ cells seem to occur in much higher counts in Class IV (1736.7
± 522.0) than Class III LN (898.5 ± 17.68) p=0.084. 

Conclusion: Urinary CD8+, CD4+, and CD14+ cells are highly sensitive and specific markers for detecting proliferative LN. A low CD4: CD8 ratio provides a further clue. The cell counts correlate with proteinuria. CD14 cell counts may be a potential biomarker to differentiate between the different classes of proliferative LN. 

Comparison between the two groups according to CD3+ CD8+/ml, CD3+ CD4+/ml and CD14+/ml

Comparison between the different classes of LN according to CD3+ CD8+/ml, CD3+ CD4+/ml and CD14+/ml.

A dot plot of flow cytometric analysis of urinary T cells and monocytes in a patient with lupus nephritis showing increased both CD4+ and CD8+ T cells and macrophages -dim CD4 expression and CD14 positive -not shown–


Disclosure: A. El Gerby, None; A. Abdelati, None; H. Donia, None; N. Eshak, None.

To cite this abstract in AMA style:

El Gerby A, Abdelati A, Donia H, Eshak N. Urinary Cellular Profile as a Biomarker for Proliferative Lupus Nephritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/urinary-cellular-profile-as-a-biomarker-for-proliferative-lupus-nephritis/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARP Annual Meeting 2019

ACR Meeting Abstracts - https://acrabstracts.org/abstract/urinary-cellular-profile-as-a-biomarker-for-proliferative-lupus-nephritis/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology